Yi Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yi Zhao has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Ziyi Yu
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
8 shared publicationsChuanpeng Zhang
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
5 shared publicationsFeixiang Sun
Nanjing Medical University
5 shared publicationsYing Tong
Nanjing Medical University
5 shared publicationsSusu Yang
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4 shared publicationsHong Pan
Department of Breast Surgery The First Affiliated Hospital with Nanjing Medical University Nanjing China
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 14 February 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-16
ZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK/PI3K/AKT activation in a ceRNA manner
Background: Circular RNAs are highly stable regulatory RNAs that have been increasingly associated with tumorigenesis and progression. However, the role of many circRNAs in triple-negative breast cancer (TNBC) and the related mechanisms have not been elucidated. Methods: In this study, we screened circRNAs with significant expression differences in the RNA sequencing datasets of TNBC and normal breast tissues and then detected the expression level of circRPPH1 by qRT‒PCR. The biological role of circRPPH1 in TNBC was then verified by in vivo and in vitro experiments. Mechanistically, we verified the regulatory effects between circRPPH1 and ZNF460 and between circRPPH1 and miR-326 by chromatin immunoprecipitation (ChIP), fluorescence in situ hybridization assay, dual luciferase reporter gene assay and RNA pull-down assay. In addition, to determine the expression of associated proteins, we performed immunohistochemistry, immunofluorescence, and western blotting. Results: The upregulation of circRPPH1 in TNBC was positively linked with a poor prognosis. Additionally, both in vivo and in vitro, circRPPH1 promoted the biologically malignant behavior of TNBC cells. Additionally, circRPPH1 may function as a molecular sponge for miR-326 to control integrin subunit alpha 5 (ITGA5) expression and activate the focal adhesion kinase (FAK)/PI3K/AKT pathway. Conclusion: Our research showed that ZNF460 could promote circRPPH1 expression and that the circRPPH1/miR-326/ITGA5 axis could activate the FAK/PI3K/AKT pathway to promote the progression of TNBC. Therefore, circRPPH1 can be used as a therapeutic or diagnostic target for TNBC.
- 14 February 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-16
Top Cited PapersOpen AccessZNF460-mediated circRPPH1 promotes TNBC progression through ITGA5-induced FAK/PI3K/AKT activation in a ceRNA manner
Background: Circular RNAs are highly stable regulatory RNAs that have been increasingly associated with tumorigenesis and progression. However, the role of many circRNAs in triple-negative breast cancer (TNBC) and the related mechanisms have not been elucidated. Methods: In this study, we screened circRNAs with significant expression differences in the RNA sequencing datasets of TNBC and normal breast tissues and then detected the expression level of circRPPH1 by qRT‒PCR. The biological role of circRPPH1 in TNBC was then verified by in vivo and in vitro experiments. Mechanistically, we verified the regulatory effects between circRPPH1 and ZNF460 and between circRPPH1 and miR-326 by chromatin immunoprecipitation (ChIP), fluorescence in situ hybridization assay, dual luciferase reporter gene assay and RNA pull-down assay. In addition, to determine the expression of associated proteins, we performed immunohistochemistry, immunofluorescence, and western blotting. Results: The upregulation of circRPPH1 in TNBC was positively linked with a poor prognosis. Additionally, both in vivo and in vitro, circRPPH1 promoted the biologically malignant behavior of TNBC cells. Additionally, circRPPH1 may function as a molecular sponge for miR-326 to control integrin subunit alpha 5 (ITGA5) expression and activate the focal adhesion kinase (FAK)/PI3K/AKT pathway. Conclusion: Our research showed that ZNF460 could promote circRPPH1 expression and that the circRPPH1/miR-326/ITGA5 axis could activate the FAK/PI3K/AKT pathway to promote the progression of TNBC. Therefore, circRPPH1 can be used as a therapeutic or diagnostic target for TNBC.
- Open Access
- 22 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Immune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Introduction: Locoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.Methods: We retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.Results: We found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup (p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup (p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor (p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors (p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors (p = 0.037).Conclusion: Our study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.
- 22 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1)
Open AccessImmune cells within tertiary lymphoid structures are associated with progression‐free survival in patients with locoregional recurrent breast cancer
Introduction: Locoregional recurrent breast cancers have a poor prognosis. Little is known about the prognostic impact of immune microenvironment, and tertiary lymphoid structures (TLSs) in particular have not been reported. Thus, we aimed to characterize the immune microenvironment in locoregional recurrent breast tumors and to investigate its relationship with prognosis.Methods: We retrospectively included 112 patients with locoregional recurrent breast cancer, and hematoxylin–eosin staining and immunohistochemical staining (CD3, CD4, CD8, CD19, CD38, and CD68) were performed on locoregional recurrent tumor samples. The association of immune cells and TLSs with progression‐free survival (PFS) were analyzed by survival analysis.Results: We found more immune cells in the peritumor than stroma. After grouping according to estrogen receptor (ER) status, a low level of peritumoral CD3+ cells in ER+ subgroup (p = 0.015) and a low level of stromal CD68+ cells in ER− subgroup (p = 0.047) were both associated with longer PFS. TLSs were present in 68% of recurrent tumors, and CD68+ cells within TLSs were significantly associated with PFS as an independent prognostic factor (p = 0.035). TLSs and immune cells (CD3, CD38, and CD68) within TLSs were associated with longer PFS in ER− recurrent tumors (p = 0.044, p = 0.012, p = 0.050, p < 0.001, respectively), whereas CD38+ cells within TLSs were associated with shorter PFS in ER+ recurrent tumors (p = 0.037).Conclusion: Our study proposes potential predictors for the clinical prognosis of patients with locoregional recurrent breast cancer, emphasizing the prognostic value of immune cells within TLSs, especially CD68+ cells.
- Open Access
- 6 September 2023
- Published by Springer Nature in Research Square
Characteristics and survival of multifocal/multicentric breast cancer: a retrospective study of 415 cases
Objectives: This study was to compare the clinicopathological and prognostic characteristics of multifocal/multicentric (MF/MC) with unifocal (UF) breast cancer to study the determinants of cancer multiplicity in survival. Methods: A retrospective analysis of 83 MF/MC and 332 UF breast cancer patients was conducted. Clinicopathological characteristics and prognostic indicators were compared. Results: MF/MC breast cancer were more likely to have lymph node metastasis and lymph vascular/perineural invasion. There was a statistically significant difference in the LRFS rate. Cancer multiplicity was not an independent prognostic factor. Conclusion: MF/MC breast cancer are more aggressive. However, cancer multiplicity did not affect prognosis.
- 6 September 2023
- Published by Springer Nature in Research Square
Open AccessCharacteristics and survival of multifocal/multicentric breast cancer: a retrospective study of 415 cases
Objectives: This study was to compare the clinicopathological and prognostic characteristics of multifocal/multicentric (MF/MC) with unifocal (UF) breast cancer to study the determinants of cancer multiplicity in survival. Methods: A retrospective analysis of 83 MF/MC and 332 UF breast cancer patients was conducted. Clinicopathological characteristics and prognostic indicators were compared. Results: MF/MC breast cancer were more likely to have lymph node metastasis and lymph vascular/perineural invasion. There was a statistically significant difference in the LRFS rate. Cancer multiplicity was not an independent prognostic factor. Conclusion: MF/MC breast cancer are more aggressive. However, cancer multiplicity did not affect prognosis.
- Open Access
- 3 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8815-8824
Multifocal/multicentric breast cancer: Does each focus matter?
Background: Multifocal (MF) and multicentric (MC) breast cancer cases have been increasingly diagnosed owing to the extensive use of improved preoperative breast imaging. The current tumor‐node‐metastasis staging system uses the dimension of the largest tumor and recommends reporting the pathological features of the largest tumor in MF/MC breast cancers.Aim: This study aimed to explore whether the largest or aggregate dimensions of MF and MC breast cancers can better predict tumor behavior. We also attempted to study the histological and biological heterogeneities of separate foci in MF and MC breast cancers to determine whether it was necessary to examine each lesion.Methods: We retrospectively analyzed 121 patients with MF/MC (103 with MF and 18 with MC) breast cancers and 484 patients with unifocal breast cancer who were treated at the First Affiliated Hospital of Nanjing Medical University. Two methods were used to record the T stage (using the dimensions of the largest lesion and aggregate dimensions of all lesions). The histological grade, immunohistochemical parameters, and molecular subtypes of the largest lesion and other lesions in MF/MC breast cancers were studied to assess intertumoral heterogeneity.Results: The use of aggregate dimensions upstaged 63 patients with MF/MC breast cancers to a more advanced stage and removed the independent effect of cancer multiplicity on lymph node positivity compared with the use of the largest dimension. Mismatches were found in the pathological type (9.9%), histological grade (4.1%), and molecular subtype (8.3%) among different foci.Conclusion: The tendency of MF/MC breast tumors to metastasize may be related to tumor load, which can be better predicted by the aggregate dimensions of all foci. The use of the current staging systems may require further evaluation and modification. Intertumoral heterogeneity indicates the necessity for pathological and immunohistochemical assessments of each lesion in patients with MF/MC breast cancers.
- 3 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8815-8824
Open AccessMultifocal/multicentric breast cancer: Does each focus matter?
Background: Multifocal (MF) and multicentric (MC) breast cancer cases have been increasingly diagnosed owing to the extensive use of improved preoperative breast imaging. The current tumor‐node‐metastasis staging system uses the dimension of the largest tumor and recommends reporting the pathological features of the largest tumor in MF/MC breast cancers.Aim: This study aimed to explore whether the largest or aggregate dimensions of MF and MC breast cancers can better predict tumor behavior. We also attempted to study the histological and biological heterogeneities of separate foci in MF and MC breast cancers to determine whether it was necessary to examine each lesion.Methods: We retrospectively analyzed 121 patients with MF/MC (103 with MF and 18 with MC) breast cancers and 484 patients with unifocal breast cancer who were treated at the First Affiliated Hospital of Nanjing Medical University. Two methods were used to record the T stage (using the dimensions of the largest lesion and aggregate dimensions of all lesions). The histological grade, immunohistochemical parameters, and molecular subtypes of the largest lesion and other lesions in MF/MC breast cancers were studied to assess intertumoral heterogeneity.Results: The use of aggregate dimensions upstaged 63 patients with MF/MC breast cancers to a more advanced stage and removed the independent effect of cancer multiplicity on lymph node positivity compared with the use of the largest dimension. Mismatches were found in the pathological type (9.9%), histological grade (4.1%), and molecular subtype (8.3%) among different foci.Conclusion: The tendency of MF/MC breast tumors to metastasize may be related to tumor load, which can be better predicted by the aggregate dimensions of all foci. The use of the current staging systems may require further evaluation and modification. Intertumoral heterogeneity indicates the necessity for pathological and immunohistochemical assessments of each lesion in patients with MF/MC breast cancers.
- Open Access
- 2 February 2023
- Published by Springer Nature in Research Square
Lawsone inhibits the proliferation and metastasis of residual breast cancer cells after microwave ablation by inducing cellular inhibitory autophagy through NCAPG/AURKB/AKT/mTOR axis
Microwave ablation (MWA) is increasingly used in clinical treatment and research of breast cancer, which has good therapeutic effect on primary and metastatic lesions. However, microwave ablation may lead to residual tumor cells due to incomplete ablation. The biological characteristics of residual tumor cells are unknown, and it is necessary to explore new adjuvant treatment methods to achieve better therapeutic effect. In this study, we demonstrated that the migration ability of residual breast cancer cells was enhanced after microwave ablation, but the proliferation ability was not significantly changed. Lawsone, an active ingredient in Chinese herbal medicine, significantly inhibited the proliferation and metastasis of residual breast cancer cells after microwave ablation in vivo and in vitro, and had synergistic effects with microwave ablation therapy. Mechanistic studies have shown that Lawsone exerts its anti-proliferation and anti-migration ability mainly by targeting NCAPG in residual breast cancer after microwave ablation. In addition, Lawsone-induced cellular inhibitory autophagy also plays a key role in its anticancer effect. In addition, NCAPG interacts with AURKB protein and jointly participates in the regulation of AKT/mTOR pathway to affect autophagy process. In short, these consequences demonstrate that Lawsone exerts its anti-proliferation and anti-metastasis effects on residual breast cancer cells after microwave ablation mainly by inhibiting NCAPG/AURKB/AKT/mTOR axis and inducing inhibitory autophagy, which provides more options for adjuvant therapy after microwave ablation.
- 2 February 2023
- Published by Springer Nature in Research Square
Open AccessLawsone inhibits the proliferation and metastasis of residual breast cancer cells after microwave ablation by inducing cellular inhibitory autophagy through NCAPG/AURKB/AKT/mTOR axis
Microwave ablation (MWA) is increasingly used in clinical treatment and research of breast cancer, which has good therapeutic effect on primary and metastatic lesions. However, microwave ablation may lead to residual tumor cells due to incomplete ablation. The biological characteristics of residual tumor cells are unknown, and it is necessary to explore new adjuvant treatment methods to achieve better therapeutic effect. In this study, we demonstrated that the migration ability of residual breast cancer cells was enhanced after microwave ablation, but the proliferation ability was not significantly changed. Lawsone, an active ingredient in Chinese herbal medicine, significantly inhibited the proliferation and metastasis of residual breast cancer cells after microwave ablation in vivo and in vitro, and had synergistic effects with microwave ablation therapy. Mechanistic studies have shown that Lawsone exerts its anti-proliferation and anti-migration ability mainly by targeting NCAPG in residual breast cancer after microwave ablation. In addition, Lawsone-induced cellular inhibitory autophagy also plays a key role in its anticancer effect. In addition, NCAPG interacts with AURKB protein and jointly participates in the regulation of AKT/mTOR pathway to affect autophagy process. In short, these consequences demonstrate that Lawsone exerts its anti-proliferation and anti-metastasis effects on residual breast cancer cells after microwave ablation mainly by inhibiting NCAPG/AURKB/AKT/mTOR axis and inducing inhibitory autophagy, which provides more options for adjuvant therapy after microwave ablation.
- 21 March 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (S1) , 231
Correction to: Endoscope-Assisted Minimally Invasive Surgery for the Treatment of Glandular Gynecomastia
- 21 March 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (S1) , 231
Correction to: Endoscope-Assisted Minimally Invasive Surgery for the Treatment of Glandular Gynecomastia
- 2 March 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (6) , 2655-2664
Endoscope-Assisted Minimally Invasive Surgery for the Treatment of Glandular Gynecomastia
Background Gynecomastia (GYN) is the most common benign disease in males. A vacuum-assisted biopsy is a minimally invasive surgical technique for GYN treatment that achieves satisfactory aesthetic results. However, due to the operation under non-direct vision, it is difficult to localize the bleeding points and assess the residual glandular tissue. Endoscopy was applied to observe the operative field after subcutaneous mastectomy. The present study aimed to recommend our initial experience in glandular GYN with endoscope-assisted minimally invasive subcutaneous mastectomy. Methods A total of 34 patients diagnosed with glandular GYN (50 breasts), treated with endoscope-assisted minimally invasive surgery at The First Affiliated Hospital with Nanjing Medical University between June 2018 and June 2020, were enrolled in this study. According to Simon’s classification of the breast, 10 was grade I, 25 was grade IIA, and 15 was grade IIB. The characteristics of patients, operative data, postoperative complications, cosmetic outcome, and patient satisfaction were recorded. Results Endoscope-assisted minimally invasive mastectomy was performed successfully in all cases. The operative duration of the operation was 55–120 min/side. The total weight of the resected tissue of the 50 breasts was 55–350 g, and the blood loss was 10–105 mL/breast. Endoscopy detected five breasts with bleeding and three with residual glandular during the operation. Postoperative bleeding occurred in 1 breast, subcutaneous seroma in 3 breasts, dysesthesia of the nipple–areolar complex in 2 breasts, and skin redundancy in a bilateral patient. None of the patients experienced severe pain, infection, nipple necrosis, and nipple retraction, a saucer-like deformity. With a median follow-up of 21 months, all patients were satisfied with their cosmetic outcome (100%), and no recurrence occurred. Conclusion Endoscope-assisted minimally invasive mastectomy could be used as a feasible technique for the treatment of glandular GYN. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online. Instructions to Authors www.springer.com/00266.
- 2 March 2022
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 46 (6) , 2655-2664
Endoscope-Assisted Minimally Invasive Surgery for the Treatment of Glandular Gynecomastia
Background Gynecomastia (GYN) is the most common benign disease in males. A vacuum-assisted biopsy is a minimally invasive surgical technique for GYN treatment that achieves satisfactory aesthetic results. However, due to the operation under non-direct vision, it is difficult to localize the bleeding points and assess the residual glandular tissue. Endoscopy was applied to observe the operative field after subcutaneous mastectomy. The present study aimed to recommend our initial experience in glandular GYN with endoscope-assisted minimally invasive subcutaneous mastectomy. Methods A total of 34 patients diagnosed with glandular GYN (50 breasts), treated with endoscope-assisted minimally invasive surgery at The First Affiliated Hospital with Nanjing Medical University between June 2018 and June 2020, were enrolled in this study. According to Simon’s classification of the breast, 10 was grade I, 25 was grade IIA, and 15 was grade IIB. The characteristics of patients, operative data, postoperative complications, cosmetic outcome, and patient satisfaction were recorded. Results Endoscope-assisted minimally invasive mastectomy was performed successfully in all cases. The operative duration of the operation was 55–120 min/side. The total weight of the resected tissue of the 50 breasts was 55–350 g, and the blood loss was 10–105 mL/breast. Endoscopy detected five breasts with bleeding and three with residual glandular during the operation. Postoperative bleeding occurred in 1 breast, subcutaneous seroma in 3 breasts, dysesthesia of the nipple–areolar complex in 2 breasts, and skin redundancy in a bilateral patient. None of the patients experienced severe pain, infection, nipple necrosis, and nipple retraction, a saucer-like deformity. With a median follow-up of 21 months, all patients were satisfied with their cosmetic outcome (100%), and no recurrence occurred. Conclusion Endoscope-assisted minimally invasive mastectomy could be used as a feasible technique for the treatment of glandular GYN. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online. Instructions to Authors www.springer.com/00266.
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 10791-10800
Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy
Circulating tumor cells (CTCs) intravasate into the bloodstream throughout early cancer stages, promoting metastasis. The tumor microenvironment plays a crucial role in disease progression and outcome. The aim of this prospective study was to investigate the associations of intratumoral and stromal tumor-infiltrating lymphocytes (TILs) with CTCs among patients receiving neoadjuvant chemotherapy (NAC). We analyzed CTCs in 30 patients with primary breast cancer before and after NAC. The numbers of intratumoral TILs (iTILs) and stromal TILs (sTILs) from pre-NAC formalin-fixed paraffin-embedded core biopsies and post-NAC surgical samples were analyzed. The associations of TILs with pathologic complete response (pCR) and outcome were also evaluated. Of the 30 patients, pCR was achieved in nine (30.0%) patients. A total of 25 (83.3%) patients were CTC-positive before NAC, and eight (26.7%) patients were CTC-positive after NAC. Neither CTC detection before NAC nor CTC after NAC was predictive of pCR. Nevertheless, the presence of CTCs after NAC was significantly associated with early metastatic relapse (P = 0.049) and worse disease-free survival (P = 0.009). After NAC, total sTILs, CD4+ T cells, and CD8+ T cells were significantly correlated with CTC detection. Increased infiltration of sTILs and CD4+ T cells was also an unfavorable prognostic factor as measured by the rate of metastatic relapse. Detection of CTCs after NAC was positively associated with the metastatic relapse of breast cancer patients. Increased infiltration of sTILs after NAC was correlated with CTCs and was found to be an unfavorable prognostic factor.
- 1 December 2019
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 11, 10791-10800
Open AccessIncreased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy
Circulating tumor cells (CTCs) intravasate into the bloodstream throughout early cancer stages, promoting metastasis. The tumor microenvironment plays a crucial role in disease progression and outcome. The aim of this prospective study was to investigate the associations of intratumoral and stromal tumor-infiltrating lymphocytes (TILs) with CTCs among patients receiving neoadjuvant chemotherapy (NAC). We analyzed CTCs in 30 patients with primary breast cancer before and after NAC. The numbers of intratumoral TILs (iTILs) and stromal TILs (sTILs) from pre-NAC formalin-fixed paraffin-embedded core biopsies and post-NAC surgical samples were analyzed. The associations of TILs with pathologic complete response (pCR) and outcome were also evaluated. Of the 30 patients, pCR was achieved in nine (30.0%) patients. A total of 25 (83.3%) patients were CTC-positive before NAC, and eight (26.7%) patients were CTC-positive after NAC. Neither CTC detection before NAC nor CTC after NAC was predictive of pCR. Nevertheless, the presence of CTCs after NAC was significantly associated with early metastatic relapse (P = 0.049) and worse disease-free survival (P = 0.009). After NAC, total sTILs, CD4+ T cells, and CD8+ T cells were significantly correlated with CTC detection. Increased infiltration of sTILs and CD4+ T cells was also an unfavorable prognostic factor as measured by the rate of metastatic relapse. Detection of CTCs after NAC was positively associated with the metastatic relapse of breast cancer patients. Increased infiltration of sTILs after NAC was correlated with CTCs and was found to be an unfavorable prognostic factor.
- Open Access
- 7 June 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (2) , 704-714
Fibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells
Fibroblast growth factor 18 (FGF18) increases cell motility and invasion in colon tumors, and is linked with ovarian and lung tumors. Furthermore, the increased expression of FGF18 mRNA and protein has been associated with poor overall survival in cancer patients. However, its function has not been investigated in breast cancer. In the present study, we demonstrated that FGF18 promoted cell growth and metastasis in vitro and stimulated tumor growth in xenograft models in vivo. FGF18 mediated the proliferation of MDA-MB-231 cells via the ERK/c-Myc signaling pathway and induced epithelial-to-mesenchymal transition (EMT) factors to promote cancer migration and invasion. The decreased expression of FGF18 was strongly correlated with the loss/reduction of p-ERK, c-Myc, N-cadherin, vimentin and Snail 1 protein in MDA-MB-231 cells. Collectively, our results indicated that FGF18 played an important role in the growth and metastasis of breast cancer via the ERK/c-Myc signaling pathway and EMT, indicating that FGF18 may be a potential molecular treatment target for breast cancer.
- 7 June 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (2) , 704-714
Open AccessFibroblast growth factor 18 promotes the growth, migration and invasion of MDA‑MB‑231 cells
Fibroblast growth factor 18 (FGF18) increases cell motility and invasion in colon tumors, and is linked with ovarian and lung tumors. Furthermore, the increased expression of FGF18 mRNA and protein has been associated with poor overall survival in cancer patients. However, its function has not been investigated in breast cancer. In the present study, we demonstrated that FGF18 promoted cell growth and metastasis in vitro and stimulated tumor growth in xenograft models in vivo. FGF18 mediated the proliferation of MDA-MB-231 cells via the ERK/c-Myc signaling pathway and induced epithelial-to-mesenchymal transition (EMT) factors to promote cancer migration and invasion. The decreased expression of FGF18 was strongly correlated with the loss/reduction of p-ERK, c-Myc, N-cadherin, vimentin and Snail 1 protein in MDA-MB-231 cells. Collectively, our results indicated that FGF18 played an important role in the growth and metastasis of breast cancer via the ERK/c-Myc signaling pathway and EMT, indicating that FGF18 may be a potential molecular treatment target for breast cancer.